翰宇药业(300199.SZ)：醋酸阿托西班注射液获得越南药品上市许可

Core Viewpoint - Hanyu Pharmaceutical has received a marketing authorization for its product "Acetate Atosiban Injection" from the Vietnam Ministry of Health, indicating a significant expansion opportunity in the Southeast Asian market [1] Company Summary - Hanyu Pharmaceutical's product, Acetate Atosiban Injection, is a competitive antagonist of oxytocin receptors, specifically designed for pregnant women with indications of preterm labor [1] - The drug is intended to delay imminent preterm birth, demonstrating good clinical efficacy and minimal side effects [1] Industry Summary - The approval of Acetate Atosiban Injection in Vietnam highlights the growing demand for effective treatments in obstetrics, particularly for managing preterm labor [1] - This development may position Hanyu Pharmaceutical favorably within the pharmaceutical industry, especially in the context of expanding its product offerings in international markets [1]